Year: 2025 | Month: July-September | Volume: 10 | Issue: 3 | Pages: 71-75
DOI: https://doi.org/10.52403/ijshr.20250308
Review of Cardiotoxicity of Remdesivir in COVID-19 Treated Patients
Aaradhita Kaler1, Jatin2, Piyush Bhutani3
1PG student, Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research, Delhi, India
2PG student, College of Physiotherapy, Pt. B. D. Sharma, University of Health Sciences, Rohtak, Haryana, India
3Student, Department of Pharmacy, Delhi Institute of Pharmaceutical Sciences and Research, Delhi, India
Corresponding Author: Aaradhita
ABSTRACT
Remdesivir was one of the first antiviral medications approved for use in emergency situations when the global COVID-19 pandemic demanded quick therapeutic responses. Although it has been shown to be effective in shortening recovery times, questions have been raised about its cardiovascular safety profile. Bradycardia and other cardiac problems in COVID-19 patients are the main topic of this research, which examines the cardiotoxic adverse drug events (ADEs) linked to remdesivir. Bradycardia was found to be the most prevalent cardiac ADE after a thorough examination of clinical trials, cohort data, and pharmacovigilance databases, including WHO and FDA reports. Arrhythmias, cardiac arrest, and QT/QRS prolongation are further consequences that have been described. Notably, the adverse chronotropic and dromotropic effects of remdesivir's metabolite, an analogue of adenosine triphosphate, may account for these cardiac consequences. The results show that remdesivir is mostly safe, although individuals with heart problems should be closely watched while they are being treated.
Keywords: COVID-19, Remdesivir, Adverse Drug Events, FDA, WHO, Cardiotoxicity.